Company News

    RSS Feed

DelMar Pharmaceuticals Receives Institutional Review Board Approval for Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM

DelMar logo

June 22, 2017 |

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced it has received Institutional Review Board (IRB) approval to conduct its pivotal Phase 3 Study in Temozolomide-Avastin (bevacizumab) Recurrent GBM (STAR-3).

“IRB approval is an essential step in initiating patient enrollment in our  … Read More

DelMar Presents Poster of Clinical Research with VAL-083 in Patients with Chemo-resistant Glioblastoma (“GBM”) at SNO’s Pediatric Neuro-Oncology Basic and Translational Research Conference

DelMar logo

June 16, 2017 |

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of unique new cancer therapies designed to save and improve lives, announced today the presentation of a poster at The Society for Neuro-Oncology’s 4th Pediatric Neuro-Oncology Basic and Translational Research Conference. The forum takes place at the Wyndham  … Read More